Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
Inhibikase Therapeutics Q4 EPS $(0.64) Beats $(0.85) Estimate, Sales $1.00K Down From $63.57K YoY
Inhibikase Therapeutics第四季度每股收益美元（0.64美元）超过预期（0.85美元），销售额低于同比6.357万美元
Inhibikase Therapeutics (NASDAQ:IKT) reported quarterly losses of $(0.64) per share which beat the analyst consensus estimate of $(0.85) by 24.71 percent. This is a 37.25 percent increase over losses of $(1.02) per share from the same period last year. The company reported $1.00 thousand in sales this quarter. This is a 98.43 percent decrease over sales of $63.57 thousand the same period last year.
Inhibikase Therapeutics（纳斯达克股票代码：IKT）公布的季度亏损为每股0.64美元（0.64美元），比分析师共识估计的美元（0.85美元）高出24.71％。与去年同期每股亏损1.02美元（1.02）相比，增长了37.25％。该公司报告本季度销售额为1,000美元。这比去年同期的63,570美元的销售额下降了98.43％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。